Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of two PrimePCR™ Assay Kits for Droplet Digital PCR (ddPCR™) (ddPCR™). This release expands Bio-Rad’s offering of predesigned ...

Bio-Rad Laboratories has announced the introduction of its new ProteoMiner® protein enrichments kits, which enable researchers to concentrate and enrich low- and medium-abundance proteins that cannot ...

Because the assay for SARS-CoV-2 is designed to target the nucleocapsid gene instead of the spike protein gene, the assay’s performance is not affected by the known coronavirus variants, as determined ...

Bio-Rad Laboratories, Inc ... this assay provides the ability for a community to determine if the ... The PREvalence ™ ddPCR ® SARS-CoV-2 Wastewater Quantification Kit includes all reagents ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ...

Accurately quantify AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit—offering reliable, efficient, and precise measurement to streamline your research workflows.

Bio-Rad Laboratories and Myriad RBM have partnered to develop and distribute immunoassay kits. The agreement combines Myriad RBM’s menu of multiplexed immunoassays with Bio-Rad’s global ...

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option ...

Because the assay for SARS-CoV-2 is designed to target the nucleocapsid gene instead of the spike protein gene, the assay’s performance is not affected by the known coronavirus variants, as determined ...

Because they are designed to target the nucleocapsid gene, the assay’s performance is not affected by known coronavirus variants as determined by in-silico analysis. The assay kit contains Bio-Rad’s ...